A Clinical Trial for the Treatment of Depression with Repetitive Transcranial Magnetic Stimulation (rTMS)

The purpose of this study is to determine whether the Cervel Neurotech rTMS device is safe and effective in the treatment of depression in people who do not get better with antidepressant medications or cannot take antidepressant medications.

Patients may participate in one of six study locations:

Emory University (Atlanta, Georgia), Principal Investigator: William M McDonald, MD        

Sheppard-Pratt Health System (Baltimore, Maryland), Principal Investigator: Scott Aaronson, MD         

Dartmouth-Hitchcock Medical Center (Lebanon, New Hampshire), Principal Investigator: Paul E Holtzheimer, MD    

Lindner Center of Hope (Mason, Ohio), Principal Investigator: John Hawkins, MD            

Butler Hospital (Providence, Rhode Island), Principal Investigator: Linda Carpenter, MDCRI

Lifetree (Salt Lake City, Utah), Principal Investigator: Clark Johnson, MD

Cervel Neurotech, Inc.
Principal Investigator: 
Varies in each of six locations
Eligibility Criteria: 

Ages Eligible for Study:       18 Years to 70 Years
Genders Eligible for Study:       Both
Accepts Healthy Volunteers:       No

Inclusion Criteria:
•    Current major depressive disorder (MDD)
•    Resistance and/or intolerance to antidepressant medication in the current depressive episode
•    On a stable psychotropic regimen prior to baseline and be willing to maintain the current regimen and dosing for the duration of the study
•    Weight less than 350 pounds


Exclusion Criteria: 

•    Current major depressive disorder episode of more than three years
•    Seizure disorder
•    History of brain injury, stroke or active central nervous system disease
•    Cardiac pacemaker, implanted device (deep brain stimulation) or metal in the brain, cervical spinal cord, or upper thoracic spinal cord unless deemed MRI-safe
•    Active suicidal intent or plan
•    Other significant psychiatric disorder
•    Alcohol or substance dependence or abuse
•    Prior treatment with transcranial magnetic stimulation
•    Have failed to clinically remit to an adequate trial of electroconvulsive therapy or vagus nerve stimulation
•    If female, pregnant or lactating or planning to become pregnant within the next three months


Contact ADAA

8701 Georgia Ave. #412
Silver Spring, MD 20910


Contact ADAA

Request Publications



ADAA is a national nonprofit organization dedicated to the prevention, treatment, and cure of anxiety, OCD, PTSD, depression, and related disorders and to improving the lives of all people who suffer from them.


Privacy Policy 
© ADAA, 2010-2014